skip to main content

AF Anticoagulation in CKD — PSA MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiologyAF Anticoagulation in CKDPSAMRCP Part 1MRCGP AKTUKMLAPARA

A frail 82-year-old with non-valvular atrial fibrillation weighs 48 kg and has serum creatinine 118 micromol/L; the laboratory reports eGFR 43 mL/min/1.73 m². A DOAC is being considered. What must occur before selecting the agent and dose?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: DCalculate Cockcroft-Gault clearance using actual weight, then apply drug-specific criteria

Explanation lettering: B = shown as A · D = shown as B · E = shown as C · C = shown as D · A = shown as E

C is correct. SPS recommends Cockcroft-Gault creatinine clearance for DOAC dosing because eGFR can overestimate renal function, particularly in older or low-weight adults; agent-specific criteria must then be applied. A uses the wrong renal estimate. B ignores low muscle mass and body size. D confuses indication-specific regimens. E is an unsupported class-wide prohibition: several DOACs have licensed AF regimens in renal impairment.

Reference: NHS Specialist Pharmacy Service: DOAC monitoring: https://www.sps.nhs.uk/monitorings/doacs-direct-oral-anticoagulants-monitoring/ GMC: PA registration assessment content map: https://www.gmc-uk.org/education/standards-guidance-and-curricula/standards-and-outcomes/pa-and-aa-prequalification-education-framework/pa-registration-assessment-content-map